Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
StanB,
I guess you missed something....
http://files.shareholder.com/downloads/INSMED/399897590x0x690054/37e9b63d-74e7-4892-965b-a0ea6fb7cccf/INSMED-IR-Deck.pdf
See slide 48
1 $ billion for 2018, many more billions to follow.
GLTY
Poor Stan got shook lmao... Oooooops
This stock went up 130% they diluted $250,000,000 changed it after trading stopped to $350,000,000 and you all expect another 30 to 100% yeah ok
That had nothing to do with the FDA or an approval makes me wonder who all these new investors are so clueless
I will bet you my house this will not touch that not in this year give me a break
Try 30 million max this drug is a joke for a rare disease many don't have
Regardless, INSM is a great $$$$$ opportunity.
Are you going to add anything for the potential of Japan and China? If so,at least 10 billion,if not 4.5-to-6 billion.
No link Crude just simple back of the envelope calculations. What'd you think a drug that will conservatively generate $1.5B in revenue will be worth to big pharma ?
Goldman and some others will provide coverage but more importantly big pharma clearly now has INSM on their radar!
Yup! We run into the 30's very, very, soon!!!!!
$INSM doubled my position today. $45.00 target now
What a beast!
$28'S
GO FIGURE
Hopefully Goldman starts coverage on Insm after the offering. This stock used to have a price target of 57.00,so IMO,it`ll be upped back to around there by someone. This time though it`ll get there and beyond.
Chance to buy today if you missed it yesterday. Lots of upgrades already announced and the lowest I saw was $32 (Baird) and highest was $36 (Leernik).....also, Goldman Sachs will be running the $250 M offering along with Leernik (just waiting on the price).
I'm a buyer tomorrow gkta
Go figure!
I bet it`s announced that it`s completed in the morning. Insmed is using GS and others,so it`ll go off quick and easy,and the stock will rise.
That would be a bad decision. Stocks going higher. We just crossed a monster hurdle,and now we wait for the FDA approval.
I agree 100% on that, with upgraded target prices.
Moving up into 27's in AH.
Even folks in Rio Linda were buying INSM shares today. Should play out nicely this month.
$50.00 target short term
What would the market cap of INSM be if it went up 100% from here, Mr. BoilerRoom?
Numerous analysts upgrades heading our way.
$INSM going up 100% from here
I am not so sure about a gap opening tomorrow. Sometimes there are investors that would have sold if they knew it had run. Not everyone sits in front of their computer.
We may find that there are sell orders placed tonight and tomorrow morning before the open.
Lets face it--there are alot of people who own INSM that would not mind taking a profit in the fact of the North Korea and hurricane news.
GLTU
$INSM yup, good trader here...
INSM looming large on 1-hr. & 3 hr. BUZZ CLOUD.
Should make Ihub breakout boards soon.
Yup lots buying happening. Gapper tomorrow
There is nothing like a short squeeze after great news top get the rocket going.
Nobody was posting over here,and I can`t stand the YMB. This is better,so lets keep this going. I know we sold the Premie app for Iplex to shire for 11 million,but some people are confused,including myself as to what apps for Iplex we sold,if any other than for Premies,and what we still have that`s ours for Iplex. I bought this company because of iplex,,Arikace became an incredible acquisition but I definitely want to know the companies plans for Iplex. If there`s none,the stock won`t negatively react because they treated Iplex like it`s a dead dog for years and years,and if they do announce it`s alive and well,and they have plans for it,IMO,we see a big jump..
Blueeyed,
Welcome back!
From my understanding iPlex is direct free to market for short stature and ALS (off label)...
Hopefully insmed can directly get the supply from Shire...
Owned since 2005,I don`t pump. Stock is going up much higher than here,this is just the opener. I want to know about IPLEX,because if the company makes an announcement that IPLEX is free and clear of the lawsuit with Tercica/Genetec,then the we could have a monster run. It`s free and clear in October,the question is what rights do we own? Can we sell for short stature right away?Many questions,like can we take up where we left off on the MMD trial? Anyone know the answers?
Interesting info! I just added more. Been watching this all day.
Now what
The only potential wrinkle in the data related to the drug's safety. The dropout rate for patients who used ALIS and GBT was 19.6%, which was a fair bit higher than the 9% dropout rate observed in the GBT group alone. Management stated that safety issues "were predominately mild or moderate in nature and generally declined after the second month of treatment."
To give investors more context on this issue, Dr. Paul Streck, Insmed's chief medical officer, offered this commentary:
No need to pump this... going up buddy
Awesome to see posters here. Keep it up. I think we see a faster approval than we expect and the share price over 80.00,maybe to 120.00. Insmed has the only fix for this lung infection,and China and Japan are in talks with the company. Expect news on that front,which will explode the stock up. China and Japan have a bigger market for lung infections than the rest of the world combined. GLTAL
he is not out of the water yet
Good going!
Today's FDA phase III approval is a big deal. For critical patients, as well as investors.
had grabbed small lot
Filled Buy 350 INSM Limit 24.20 -- -- 12:13:51 09/05/17
Filled Buy 150 INSM Limit 24.20 -- -- 12:13:55 09/05/17
This will move up I guarantee it... Like I said my target is $50.00 a share. Easy
I am riding a few. Once all the day traders move on, INSM heads north.
INSM going $50.00 a share this week
Followers
|
93
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6485
|
Created
|
11/30/02
|
Type
|
Free
|
Moderators |
Old summary was from PRIOR to insmed taking over Transave.
Transave website:
Insmed old lead drug iplex is still being run in an external trial on Retinopathy in premature infants. Trial is fully stocked with iplex to complete phase 2b
http://www.rop.gu.se/prevention/
And there is still expanded acces program with iplex in ALS patients in italy with limited supply of iplex into 2011.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |